Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas

Pediatric Blood & Cancer
Jonathan L MettsThomas Cash

Abstract

Pediatric patients with relapsed/refractory sarcomas have poor outcomes and need novel therapies that provide disease control while maintaining an acceptable quality of life. The activity and toxicity of gemcitabine and nab-paclitaxel in combination has not been reported in pediatrics. We reviewed the records of fifteen relapsed/refractory patients and one treatment-naïve patient who received gemcitabine/nab-paclitaxel at our institution. Sixteen patients (median age 13.5 years, range 3-19 years) received 53 cycles of gemcitabine/nab-paclitaxel. Twenty-nine cycles (55%) resulted in ≥Grade 3 toxicity, with nonhematologic Grade ≥3 toxicities occurring in only eight of 53 cycles (15%). Patients received red blood cell and platelet transfusions in 23% and 4% of cycles, respectively. Grade ≥3 infectious toxicities occurred in 4% of cycles. Of 14 patients with measurable disease, there were no complete responses (CR), one partial response (PR; 7%), and six patients (43%) with stable disease (SD; median SD: 4.5 months, range: 2-19 months). In total, 31% of the patients derived clinical benefit (CR + PR + SD ≥ 4 months). Median time to progression was 72 days with a 4-month progression-free survival of 31% ± 12% and 1-year overall surv...Continue Reading

References

Aug 31, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H GelderblomA Sparreboom
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martee L HensleyDavid R Spriggs
Oct 9, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Domenico GalettaGiuseppe Colucci
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Neil DesaiPatrick Soon-Shiong
May 26, 2006·Expert Opinion on Pharmacotherapy·William J Gradishar
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naiyer A RizviMark G Kris
May 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Thomas E StinchcombeE Claire Dees
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy S AlbainJoyce O'Shaughnessy
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Apr 8, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Emilios E PakosJohn P A Ioannidis
Sep 4, 2009·Journal of Pediatric Hematology/oncology·Jaume MoraCarmen de Torres
Aug 4, 2011·Journal of Neuro-oncology·Elena PentsovaAdília Hormigo
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffManuel Hidalgo
Feb 4, 2012·Pediatric Blood & Cancer·Louis RapkinHoward M Katzenstein
Aug 31, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Libo ZhangSylvain Baruchel
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Jan 10, 2014·The Journal of Supportive Oncology·Deena LevineJustin N Baker
Aug 11, 2015·Case Reports in Rheumatology·Alexandra Perel-WinklerNazia Hussain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Babesiosis

Babesiosis is caused by parasites of the genus babesia, which are transmitted in nature by the bite of an infected tick. Discover the latest research on babesiosis here.